Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (41-50 of 144) with videos related to

Pageof 15
Sort By:
International Journal of Cardiology|August 31, 2016
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsMichel Farnier, Daniel Gaudet, Velichka Valcheva, et al.
Lipids in Health and Disease|November 18, 2011
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatinMichel Farnier, Qian Dong, Arvind Shah, et al.
Journal of Clinical Lipidology|November 20, 2023
Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period: High triglycerides in acute myocardial infarctionMarianne Zeller, Frédéric Chague, Maud Maza, et al.
Presse Medicale (Paris, France : 1983)|March 11, 2011
[Recommendations for hypercholesterolemic children]Gérald Luc, Jean-Philippe Girardet, Éric Bruckert, et al.
Journal of Clinical Medicine|December 24, 2021
Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French CardiologistsJean Ferrières, François Roubille, Michel Farnier, et al.
Journal of Clinical Lipidology|August 22, 2022
High lipoprotein(a) levels predict severity of coronary artery disease in patients hospitalized for acute myocardial infarction. Data from the French RICO surveyMichel Farnier, Frédéric Chagué, Maud Maza, et al.
The American Journal of Cardiology|October 1, 2003
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)Michel Farnier, Thomas Salko, Jonathan L Isaacsohn, et al.
Medicine|December 17, 2020
Prevalence and management of hypercholesterolemia in France, the Esteban observational studyJacques Blacher, Amélie Gabet, Alexandre Vallée, et al.
Vascular Health and Risk Management|May 24, 2014
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemiaMichel Farnier, Erluo Chen, Amy O Johnson-Levonas, et al.
Future Cardiology|April 16, 2016
Statin combination therapy and cardiovascular risk reductionPeter P Toth, Michel Farnier, Joanne E Tomassini, et al.
Pageof 15

Showing results (41-50 of 144) with videos related to

Sort By:
Pageof 15
International Journal of Cardiology|August 31, 2016
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsMichel Farnier, Daniel Gaudet, Velichka Valcheva, et al.
Lipids in Health and Disease|November 18, 2011
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatinMichel Farnier, Qian Dong, Arvind Shah, et al.
Journal of Clinical Lipidology|November 20, 2023
Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period: High triglycerides in acute myocardial infarctionMarianne Zeller, Frédéric Chague, Maud Maza, et al.
Presse Medicale (Paris, France : 1983)|March 11, 2011
[Recommendations for hypercholesterolemic children]Gérald Luc, Jean-Philippe Girardet, Éric Bruckert, et al.
Journal of Clinical Medicine|December 24, 2021
Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French CardiologistsJean Ferrières, François Roubille, Michel Farnier, et al.
Journal of Clinical Lipidology|August 22, 2022
High lipoprotein(a) levels predict severity of coronary artery disease in patients hospitalized for acute myocardial infarction. Data from the French RICO surveyMichel Farnier, Frédéric Chagué, Maud Maza, et al.
The American Journal of Cardiology|October 1, 2003
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)Michel Farnier, Thomas Salko, Jonathan L Isaacsohn, et al.
Medicine|December 17, 2020
Prevalence and management of hypercholesterolemia in France, the Esteban observational studyJacques Blacher, Amélie Gabet, Alexandre Vallée, et al.
Vascular Health and Risk Management|May 24, 2014
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemiaMichel Farnier, Erluo Chen, Amy O Johnson-Levonas, et al.
Future Cardiology|April 16, 2016
Statin combination therapy and cardiovascular risk reductionPeter P Toth, Michel Farnier, Joanne E Tomassini, et al.
Pageof 15